FY2025 EPS Estimates for Genmab A/S Reduced by William Blair

Genmab A/S (NASDAQ:GMAB) – Analysts at William Blair lowered their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued to clients and investors on Tuesday, January 21st. William Blair analyst M. Phipps now expects that the company will post earnings per share of $1.38 for the year, down from their previous forecast of $1.60. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the previous year, the business posted $0.47 earnings per share.

Other equities analysts also recently issued research reports about the stock. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday. Finally, Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $21.29 on Thursday. Genmab A/S has a one year low of $19.85 and a one year high of $31.88. The company has a market cap of $14.09 billion, a PE ratio of 20.67, a P/E/G ratio of 0.59 and a beta of 0.97. The firm’s 50 day simple moving average is $21.07 and its 200 day simple moving average is $23.98.

Institutional Trading of Genmab A/S

Large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its position in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after purchasing an additional 12,654 shares in the last quarter. HighTower Advisors LLC acquired a new position in Genmab A/S in the third quarter valued at approximately $273,000. Verition Fund Management LLC bought a new position in shares of Genmab A/S during the 3rd quarter worth approximately $709,000. FMR LLC grew its position in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares during the period. Finally, Natixis Advisors LLC increased its stake in shares of Genmab A/S by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after acquiring an additional 47,437 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.